US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at -0.19 against a street estimate of -0.17 — a miss of 11.8%.
Analysts rate Lifecore Biomedical Inc. a hold (0 buy, 4 hold, 0 sell out of 4) with an average price target of $6.28.
| Fund | Stake |
|---|---|
| Wynnefield Capital Inc | 12.41% |
| Legion Partners Asset Management, LLC | 11.77% |
| Greenhaven Road Investment Management, L.P. | 8.42% |
| 325 Capital LLC | 7.64% |
| BlackRock Inc | 5.31% |
| Vanguard Capital Management, LLC | 3.40% |
| Geode Capital Management, LLC | 2.26% |
| Morgan Stanley - Brokerage Accounts | 2.03% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lifecore Biomedical Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.